Anafranil is a tricyclic antidepressant containing clomipramine hydrochloride. It is used for OCD, depression, and panic disorder. It helps by blocking serotonin reuptake and reducing obsessive thoughts and anxiety-driven behaviours.
Anafranil, containing the active ingredient clomipramine hydrochloride, is a tricyclic antidepressant primarily used to treat obsessive-compulsive disorder (OCD), depression, and panic disorder. It is used in adults and, in selected cases, adolescents under specialist care where intrusive thoughts, compulsions, or anxiety symptoms are impairing daily function. Clomipramine works mainly by blocking serotonin reuptake (and also affects norepinephrine), which can reduce obsessive thoughts and ease anxiety-driven behaviours.
Anafranil is a tricyclic antidepressant (TCA) in the wider group of antidepressants. Its generic name is clomipramine (also written as clomipramine hydrochloride), and it has a long-standing role in OCD management, where it can be more effective than many other antidepressants for obsessive symptoms in day-to-day practice. It is not a “quick fix”, and the benefit tends to build with steady dosing over weeks rather than hours.
Common reasons clinicians prescribe clomipramine include:
Anafranil, containing the active ingredient clomipramine hydrochloride, is a tricyclic antidepressant primarily used to treat obsessive-compulsive disorder (OCD), depression, and panic disorder. It is used in adults and, in selected cases, adolescents under specialist care where intrusive thoughts, compulsions, or anxiety symptoms are impairing daily function. Clomipramine works mainly by blocking serotonin reuptake (and also affects norepinephrine), which can reduce obsessive thoughts and ease anxiety-driven behaviours.
Anafranil is a tricyclic antidepressant (TCA) in the wider group of antidepressants. Its generic name is clomipramine (also written as clomipramine hydrochloride), and it has a long-standing role in OCD management, where it can be more effective than many other antidepressants for obsessive symptoms in day-to-day practice. It is not a “quick fix”, and the benefit tends to build with steady dosing over weeks rather than hours.
Common reasons clinicians prescribe clomipramine include:
Anafranil dosing is individualized. For OCD and panic disorder, prescribers often begin low and increase gradually to reduce early side effects like drowsiness, constipation, and dizziness.
Typical prescribing patterns (doctor-directed):
Dose titration matters with TCAs. Going up too fast is a common reason people stop early, even when the medication could have worked well for OCD. For many patients, meaningful OCD symptom reduction appears after 2–6 weeks at a stable therapeutic dose, and sometimes longer for full benefit.
Taking Anafranil with food can smooth out early nausea and reduce “stomach flipping” sensations. If morning dosing causes daytime sleepiness, clinicians often move dosing later in the day rather than lowering a dose that is starting to help.
Anafranil is prescribed for obsessive-compulsive disorder, depression, panic disorder, phobias, trichotillomania, selected cases of cataplexy and narcolepsy, selected cases of enuresis, and off-label use for premature ejaculation.
Anafranil is a TCA, and that shapes both its advantages and its drawbacks. For OCD, clomipramine is often viewed as one of the most potent serotonin reuptake inhibitors in real-world practice; the trade-off is a heavier side-effect burden than many SSRIs. Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine are often tried first because they are easier to tolerate and safer in overdose. Agents like vortioxetine are used for depression and cognition symptoms, yet they are not the classic first-line choice for OCD compared with SSRIs or clomipramine.
| Option | Class | Typical place in care |
|---|---|---|
| Anafranil (clomipramine) | Tricyclic antidepressant (TCA) | OCD with strong obsessive symptoms; depression/panic in selected patients |
| Fluoxetine | SSRI | Often first-line for depression and OCD due to tolerability |
| Vortioxetine | Serotonergic antidepressant | Depression where cognitive symptoms are prominent |
One-sentence trade-off: Anafranil can work when SSRIs fall short, yet constipation, sedation, and sexual side effects stop some people from staying on it.
Anafranil is not a good fit if you have bipolar disorder, schizophrenia, a seizure tendency, heart rhythm concerns, narrow-angle glaucoma, or trouble passing urine. It also needs extra caution in older adults because constipation, confusion, and falls can become more likely. If you are taking an MAOI or other medicines that raise serotonin, this is especially important to discuss before starting.
Side effects with Anafranil are real, and they are also predictable. Clomipramine has anticholinergic effects (dry mouth, constipation, blurred vision), can cause sedation, and may affect heart rhythm in susceptible patients.
Commonly reported adverse effects include:
Serious effects that need urgent medical attention:
A small but important nuance: TCAs can worsen narrow-angle (closed-angle) glaucoma and can trigger urinary retention in men with prostate enlargement, even at doses that are helpful for OCD.
Small errors can change tolerability a lot with TCAs.
Mistakes that commonly lead to poor outcomes:
Doctors usually reach for Anafranil when the problem is dominated by obsessions and compulsions that do not respond well enough to first-line options, or when a patient previously had a clear response to clomipramine. Psychiatrists also tend to respect the side-effect profile and build the dose more slowly than with SSRIs, because constipation, sedation, and orthostatic dizziness are the reasons people quit early.
Clinical guidance for OCD pharmacotherapy expects a gradual build of benefit, often over several weeks, and many patients need a stable therapeutic dose before the change becomes obvious. A common real-life timeline is early tolerability changes in week 1–2, then reduced ritual time and urge intensity from week 3 onward, with further gains after that. NICE OCD guidance (updated documents are maintained through 2025) supports adequate duration at an effective dose before judging response and often pairs medication with CBT with exposure and response prevention. Dose changes should be paced because side effects can appear faster than symptom relief.
Anafranil is not classed as an addictive drug in the way benzodiazepines or opioids are. Still, stopping abruptly can trigger discontinuation symptoms such as nausea, insomnia, vivid dreams, irritability, and flu-like feelings. WHO medicine safety materials describe discontinuation phenomena across antidepressant classes and recommend gradual tapering when treatment ends. If you have taken it for months, a planned taper is usually far easier than a sudden stop.
Alcohol can amplify sedation, dizziness, and slowed reaction time from clomipramine, and that can be dangerous for driving or operating machinery. People who drink also report poorer sleep quality on TCAs, even if alcohol feels sedating at first. MOHAP-aligned safety counselling in the UAE typically advises avoiding alcohol with sedating psychotropic medicines because impairment is additive and unpredictable across individuals. If alcohol is a regular part of your routine, it is worth planning dosing time carefully with your prescriber.
Anafranil S.R refers to a sustained-release approach, designed to release medication more gradually across the day. Some patients experience smoother tolerability (less peak-related dizziness or nausea), while others prefer immediate-release flexibility for dose timing. The core active ingredient is still clomipramine hydrochloride, and the clinical goal is the same—consistent exposure that reduces OCD and anxiety symptoms. Switching between release patterns is a prescriber decision because timing and side effects can shift.
Sleepiness is common early on and is dose-related. Clinicians often respond by shifting more of the dose to evening, splitting the dose, or slowing titration rather than abandoning treatment immediately, since OCD benefits often come later. EMA medicine information for clomipramine supports titration strategies to improve tolerability while maintaining therapeutic intent. If sleepiness is sudden, severe, or paired with fainting or palpitations, urgent assessment is needed.
Anafranil has historically been associated with Novartis Pharma AG in many markets, and brand ownership can vary by region over time through licensing and distribution arrangements. What matters clinically is that Anafranil refers to clomipramine hydrochloride tablets at the stated strength, produced under regulated pharmaceutical quality systems. EMA documentation for clomipramine focuses on the active ingredient’s safety and efficacy profile, independent of brand owner naming conventions. If brand continuity is important for you due to tolerability, staying consistent with the same product is a reasonable preference to discuss with your prescriber.
سيتم تغليف طلبك بشكل آمن وشحنه خلال 24 ساعة. هذا هو الشكل الذي ستبدو عليه طردك بالضبط (صور لمنتج فعلي تم إرساله). له حجم ومظهر رسالة خاصة عادية (9.4×4.3×0.3 بوصة أو 24×11×0.7 سم) ولا يمكن رؤية محتوياته.
